.png)
Prognostic insights at diagnosis from the initial histology slide.
Better risk stratification to support treatment decisions.
No extra tests, no added tissue.
Overcoming the barriers of tumor heterogeneity, expensive tests, and slow results to enable timely, individualized care
%20(1).png)
DiaSurv™ delivers independent risk stratification in cutaneous melanoma using AI applied to histology slides, extending beyond AJCC8 staging, to guide individualized management.
Predicting overall survival, recurrence-free survival, and distant metastasis-free survival (DMFS)
DiaSurv™ AI-driven recurrence risk quantification in colorectal cancer delivers prognostic precision beyond staging. For stage II (T3/T4, MMR-P).
Ensuring chemotherapy is offered to those most likely to benefit while reducing unnecessary treatment.
![[digital project] image of a mobile device with a productivity app (for a productivity tools business)](https://cdn.prod.website-files.com/68bd802058541e627abf1407/68c86c9a4770fd2dec86bc6c_7.png)
DiaSurv™ AI recurrence score and survival test that refines prognosis in early-stage HR+/HER2- breast cancer by characterizing tumor biology, quantifying recurrence risk, and predicting overall survival and disease progression.
DiaSurv™ AI-driven prediction of HRD status and treatment response to PARP inhibitors in ovarian cancer, delivering clear and comprehensive results to guide treatment strategies for HRD positive patients.
DiaSurv™ starts with the same histology slide already used for diagnosis. No extra tissue or tests are required.
%20(1030%20x%20624%20px)%20(2).png)
Deep learning models analyze the slide at the pixel level, capturing prognostic features not visible to the human eye.
%20(1030%20x%20624%20px)%20(1).png)
DiaSurvTM generates explainable, individualized survival predictions, validated on large multi-center cohorts, supporting therapy and follow-up decisions.
DiaSurv™ is for Research Use Only. Not for use in diagnostic procedures. Information updated on 17th September 2025 – Version V2MKP
